期刊文献+

替比夫定联合阿德福韦酯长期治疗活动性乙型肝炎肝硬化的临床观察 被引量:11

Clinical Observation of Telbivudine Combined with Adefovir Dipivoxil in Long-term Treatment of Active Hepatitis B Cirrhosis
原文传递
导出
摘要 目的:观察替比夫定联合阿德福韦酯长期治疗活动性乙型肝炎肝硬化的疗效及安全性。方法:76例活动性乙型肝炎肝硬化患者,按随机数字表法分为观察组和对照组,各38例。对照组患者给予阿德福韦酯10 mg,qd;观察组患者在对照组基础上加用替比夫定600 mg,qd。两组患者均连续服用2年。观察两组患者治疗后血清胆红素(TBIL)、白蛋白(ALB)、丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、乙型肝炎病毒的脱氧核糖核酸(HBV-DNA)转阴率、血清病毒学指标,并比较两组患者的临床疗效及不良反应。结果:治疗后,观察组患者的AST、ALB、ALT、TBIL水平均显著优于对照组,两组比较差异有统计学意义(P<0.05);观察组患者治疗后1、2年HBV-DNA病毒转阴率、血清病毒下降幅度均显著高于对照组,两组比较差异有统计学意义(P<0.05);观察组患者的临床总有效率显著高于对照组,两组比较差异有统计学意义(P<0.05);两组患者均未见明显不良反应发生。结论:替比夫定联合阿德福韦酯可以显著地改善乙型肝炎肝硬化患者肝功能水平,长期疗效良好,且安全性高。 OBJECTIVE:To observe therapeutic efficacy and safety of telbivudine combined with adefovir dipivoxil in long-term treatment of active hepatitis B cirrhosis. METHODS:76 patients with active hepatitis B cirrhosis in our hospital were randomly divided into observation group and control group,with 38 cases in each group. Control group was treated with adefovir dipivoxil 10 mg,qd;observation group was additionally treated with telbivudine 600 mg,qd,on the basis of control group. Both groups received 2-year consecutive treatment. TBIL,ALB,ALT,AST,rate of HBV-DNA negative conversion and serum virological index were compared between 2 groups after treatment,and clinical efficacy and ADR were also compared between 2 groups.RESULTS:After treatment,the levels of AST,ALB,ALT and TBIL in observation group were significantly better than the control group,with statistical significance(P〈0.05);the rate of HBV-DNA negative conversion,the decreased of serum virus in observation group were significantly higher than control group after 1 and 2 years treatment,with statistical significance(P〈0.05). The total effective rate of observation group was significantly higher than that of control group,with statistically significance(P〈0.05).No obvious ADR was found in 2 groups. CONCLUSIONS:Telbivudine combined with adefovir dipivoxil can significantly improve the liver function of patients with hepatitis B cirrhosis and have good long-term therapeutic efficacy with high safety.
出处 《中国药房》 CAS 北大核心 2015年第35期4984-4986,共3页 China Pharmacy
关键词 替比夫定 阿德福韦酯 联合用药 乙型肝炎肝硬化 长期疗效 Telbivudine Adefovir dipivoxil Drug combination Hepatitis B cirrhosis Long-term therapeutic efficacy
  • 相关文献

参考文献12

二级参考文献93

共引文献2070

同被引文献68

  • 1Zhang X,Zhang Q,Peng Q,et al.Hepatitis B virus preslderived lipopeptide functionalized liposomes for targeting of hepatic cells[J].Biomaterials,2014,35(23):6 130.
  • 2Wu ZF,Zhou XH,Hu YW,et al.TLR4-dependant immune response,but not hepatitis B virus reactivation,is important in radiation-induced liver disease of liver cancer radiotherapy[J].Cancer Immunol Immunother,2014,63(3):235.
  • 3姜政伟,王东清.介入治疗联合抗病毒治疗乙肝相关肝癌的疗效分析[J].国际病毒学杂志,2015,22(z1):199.
  • 4Wang J,Zhu R,Gao B,et al.The enhanced immune response of hepatitis B virus DNA vaccine using Si O2@LDH nanoparticles as an adjuvant[J].Biomaterials,2014,35(1):466.
  • 5Tsai MC,Chen CH,Hung CH,et al.A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B:a match-control study[J].Clin Microbiol Infect,2014,20(2):90.
  • 6Seto WK,Lam YF,Fung J,et al.Changes of HBs Ag and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment[J].J Gastroenterol Hepatol,2014,29(5):1 028.
  • 7Spaziante M,Biliotti E,Grieco S,et al.Anti-HBs seroconversion during treatment with entecavir in a patient with chronic hepatitis B virus infection on hemodialysis[J].J Med Virol,2014,86(1):139.
  • 8焦建中,李晓云,吴永胜,郭玲,李晓莉.替比夫定治疗乙型肝炎肝硬化的临床疗效分析[J].肝脏,2010,15(5):356-357. 被引量:2
  • 9颜见,姚志成,邓美海.乙型肝炎病毒相关性肝癌发生的分子机制研究进展[J].中华普通外科学文献(电子版),2012,6(5):50-54. 被引量:12
  • 10赵明聪.替比夫定联合阿德福韦酯对活动性乙肝肝硬化长期治疗的疗效[J].当代医学,2013,19(15):131-132. 被引量:10

引证文献11

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部